Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 52-Week High Following Analyst Upgrade

Key Points

• Kiniksa Pharmaceuticals International reached a new 52-week high of $39.57 following a price target upgrade by Citigroup from $45.00 to $50.00, maintaining a buy rating on the stock.
• Multiple brokerages are adjusting their ratings on KNSA, with Zacks Research downgrading it from "strong-buy" to "hold," while others have set price targets as high as $60.00.
• Insiders have sold a significant number of shares recently, with a total of 596,839 shares valued at over $20 million sold over the last quarter, indicating possible profit-taking strategies among directors.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report)'s share price reached a new 52-week high during trading on Monday after Citigroup raised their price target on the stock from $45.00 to $50.00. Citigroup currently has a buy rating on the stock. Kiniksa Pharmaceuticals International traded as high as $39.57 and last traded at $39.37, with a volume of 280711 shares. The stock had previously closed at $38.64.

Several other brokerages have also issued reports on KNSA. Zacks Research lowered Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "hold" rating in a research note on Monday, October 6th. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a report on Friday, October 3rd. Jefferies Financial Group boosted their price objective on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a report on Tuesday, July 29th. Wedbush boosted their price objective on Kiniksa Pharmaceuticals International from $38.00 to $44.00 and gave the company an "outperform" rating in a report on Monday, October 13th. Finally, TD Cowen began coverage on shares of Kiniksa Pharmaceuticals International in a research report on Monday, September 29th. They issued a "buy" rating and a $60.00 price target on the stock. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $46.86.

Insider Buying and Selling

In related news, Director Thomas Malley sold 78,233 shares of Kiniksa Pharmaceuticals International stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $33.09, for a total transaction of $2,588,729.97. Following the sale, the director directly owned 12,546 shares in the company, valued at approximately $415,147.14. This trade represents a 86.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider John F. Paolini sold 29,325 shares of the company's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $32.55, for a total value of $954,528.75. Following the completion of the transaction, the insider owned 57,403 shares of the company's stock, valued at $1,868,467.65. This trade represents a 33.81% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 596,839 shares of company stock valued at $20,357,964 over the last quarter. Corporate insiders own 53.48% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KNSA. GAMMA Investing LLC increased its stake in shares of Kiniksa Pharmaceuticals International by 84.8% during the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after purchasing an additional 568 shares during the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth $301,000. Asset Management One Co. Ltd. bought a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth $41,000. Wealthquest Corp purchased a new stake in Kiniksa Pharmaceuticals International in the 1st quarter worth about $42,000. Finally, AMI Asset Management Corp raised its stake in Kiniksa Pharmaceuticals International by 50.3% in the 1st quarter. AMI Asset Management Corp now owns 77,688 shares of the company's stock valued at $1,725,000 after acquiring an additional 26,010 shares during the period. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals International Price Performance

The firm has a market capitalization of $2.90 billion, a PE ratio of 981.10 and a beta of 0.16. The company's fifty day simple moving average is $35.85 and its 200 day simple moving average is $29.82.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The company had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.